CYBN
Cybin Inc.
$8.28
+0.10
(+1.22%)
Mkt Cap
413.02M
Volume
716,528
52W Range
4.81-10.7199
Sector
Healthcare
Beta
0.79
EPS (TTM)
-4.19
P/E Ratio
N/A
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 |
|---|---|
| Revenue | 0 |
| Net Income | (113.14M) |
| EPS | -0.61 |
| Free Cash Flow | (103.27M) |
| FCF / Share | -0.56 |
| Operating CF | (101.30M) |
| Total Assets | 258.62M |
| Total Debt | 0 |
| Cash & Equiv | 135.02M |
| Book Value | 237.20M |
| Return on Equity | -0.48 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.72M) | (18.07M) | (30.58M) | (10.54M) | (57.19M) | (14.82M) |
| EPS | -1.39 | -0.81 | -1.46 | -0.53 | -2.86 | -0.12 |
| Free Cash Flow | (34.92M) | (21.86M) | (22.20M) | (27.43M) | (26.19M) | (27.45M) |
| FCF / Share | -1.44 | -0.98 | -1.06 | -1.41 | -1.31 | -0.22 |
| Operating CF | (34.48M) | (21.69M) | (21.11M) | (27.12M) | (25.85M) | (27.21M) |
| Total Assets | 181.25M | 154.73M | 258.62M | 253.55M | 262.39M | 284.65M |
| Total Debt | 28.89M | 32.66M | 0 | 0 | 133,000 | 212,000 |
| Cash & Equiv | 83.75M | 87.12M | 135.02M | 136.29M | 154.32M | 183.28M |
| Book Value | 139.00M | 111.39M | 237.20M | 240.24M | 255.02M | 279.83M |
| Return on Equity | -0.24 | -0.16 | -0.13 | -0.04 | -0.22 | -0.05 |
CYBN News
No news available for CYBN.